Literature DB >> 15033055

[Clinical study of 23 patients with ataxic hemiparesis].

Adrià Arboix1.   

Abstract

BACKGROUND AND
OBJECTIVE: To characterize the clinical features, etiology and prognosis in ataxic hemiparesis syndrome. PATIENTS AND
METHOD: Descriptive study of 23 patients with ataxic hemiparesis included in the Sagrat Cor Hospital of Barcelona Stroke Registry over a 12 year period.
RESULTS: Ataxic hemiparesis was caused by a lacunar infarct in 87% of patients, by atherothrombotic infarcts in 8.7% and by cardioembolic infarct in 4.3%. Ataxic hemiparesis accounted for 0.9% of all acute strokes (n = 2,500), 1.25% of all cerebral infarcts (n = 1,840), and 4.1% of all lacunar infarcts (n = 484). Internal capsule (22%), pons (13%), and corona radiata involvement (9%) were the most frequent cerebral topographies. Absence of in hospital mortality and absence of neurological deficit at discharge from the hospital were present in 39% of the patients.
CONCLUSIONS: Lacune hypothesis is present in ataxic hemiparesis syndrome. Ataxic hemiparesis is caused by a lacunar infarct in 87% of patients. The internal capsule topography is the most frequent and the prognosis in ataxic hemiparesis is good.

Entities:  

Mesh:

Year:  2004        PMID: 15033055     DOI: 10.1016/s0025-7753(04)74229-3

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  3 in total

1.  Ataxic hemiparesis from strategic frontal white matter infarction with crossed cerebellar diaschisis.

Authors:  Alexander C Flint; MaryAlice C Naley; Clinton B Wright
Journal:  Stroke       Date:  2005-11-23       Impact factor: 7.914

2.  Diffusion weighted imaging in ataxic hemiparesis.

Authors:  Akiyuki Hiraga; Akiyuki Uzawa; Ikuo Kamitsukasa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-06-05       Impact factor: 10.154

Review 3.  The Potential Impact of Neuroimaging and Translational Research on the Clinical Management of Lacunar Stroke.

Authors:  Salvatore Rudilosso; Alejandro Rodríguez-Vázquez; Xabier Urra; Adrià Arboix
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.